Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders. Primarily affecting the pulmonary interstitium, these diseases are characterized by inflammation, fibrosis, or a combination of both. This article provides a comprehensive overview of ILDs, their pathophysiology, diagnosis, and management strategies.
ILDs are typically the result of an exaggerated or misdirected repair response to lung injury. Inflammatory cells infiltrate the interstitium, leading to fibroblast proliferation, collagen deposition, and eventual architectural distortion. This process results in impaired gas exchange, restrictive lung physiology, and respiratory failure if unchecked.
Diagnosis of ILDs requires a thorough clinical evaluation, including a detailed history and physical examination. High-resolution computed tomography (HRCT) is the imaging modality of choice, revealing characteristic patterns such as ground-glass opacities, reticulations, and honeycombing. Pulmonary function tests show a restrictive pattern with reduced diffusion capacity. Lung biopsy, though not always necessary, can provide definitive diagnosis in certain cases.
Management of ILDs is complex and multifaceted. It primarily focuses on halting disease progression and improving quality of life. Treatment options include corticosteroids, immunosuppressive agents, and antifibrotic drugs. Lung transplantation may be considered in advanced cases. Multidisciplinary team involvement is crucial for optimal patient care.
Interstitial lung diseases present a significant challenge due to their diversity and complex pathophysiology. Early recognition, accurate diagnosis, and appropriate management can significantly improve patient outcomes. As our understanding of these diseases continues to evolve, so too will our therapeutic strategies, underscoring the importance of ongoing research in this field.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation